Prof Myung-Ju Ahn speaks to ecancer at the ESMO Asia Virtual Congress about the latest data for managing ALK NSCLC patients with a focus on Asian populations.
Much of the information regards a few recent large profile studies including J-ALTA and ALTA-1L , revealing the unmet needs, challenges, and treatment selection in first line (1L), 2L or 2L setting.
Prof Ahn then compares updated Asian vs non-Asian population data from the aforementioned studies and latest data from J-ALEX and ALESIA.
She rounds off by discussing the implications that the results from these 4 studies will have on clinical practise.
This programme has been supported by an unrestricted educational grant from Takeda.